RavenQuest BioMed Inc.
Other OTCTotal Valuation
RavenQuest BioMed Inc. carries a market capitalization of 1,236.00, placing it among publicly traded companies globally. Its enterprise value stands at 60.04M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 1,236.00 |
| Enterprise Value | 60.04M |
Share Statistics
RavenQuest BioMed Inc. currently has 123.62M shares outstanding.
| Shares Outstanding | 123.62M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 30.23, and the price-to-book ratio stands at -1.01.
| PE Ratio | N/A |
| PS Ratio | 30.23 |
| PB Ratio | -1.01 |
| P/TBV Ratio | 11.26 |
| P/FCF Ratio | 7.37 |
| P/OCF Ratio | -49.22 |
Enterprise Valuation
| EV / Sales | 39.45 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | 6.38 |
Financial Position
RavenQuest BioMed Inc. maintains a current ratio of 0.49, meaning it holds 0.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 71.99, indicating elevated leverage, while an interest coverage ratio of -4.52 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.49 |
| Quick Ratio | 0.30 |
| Debt / Equity | 71.99 |
| Debt / EBITDA | -1.03 |
| Interest Coverage | -4.52 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -70.76 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 4.64 |
Income Statement
Over the trailing twelve months, RavenQuest BioMed Inc. generated 1.52M in revenue and converted that into -32.35M in net income, yielding earnings per share of -0.28. EBITDA reached -14.36M, while operating income came in at -18.26M.
| Revenue | 1.52M |
| Gross Profit | 892,376.00 |
| Operating Income | -18.26M |
| Pretax Income | -32.93M |
| Net Income | -32.35M |
| EBITDA | -14.36M |
| EBIT | -18.26M |
| Earnings Per Share (EPS) | -0.28 |
Balance Sheet
RavenQuest BioMed Inc. holds 749,135.00 in cash and equivalents against 14.78M in total debt, resulting in a net debt position of 14.03M. Total book value stands at -45.58M, with working capital of -2.88M providing operational flexibility.
| Cash & Cash Equivalents | 749,135.00 |
| Total Debt | 14.78M |
| Net Debt | 14.03M |
| Equity (Book Value) | -45.58M |
| Book Value Per Share | -0.39 |
| Working Capital | -2.88M |
Cash Flow
RavenQuest BioMed Inc. produced -934,832.00 in operating cash flow over the past twelve months. After subtracting -7.17M in capital expenditures, free cash flow totaled -8.11M - equivalent to -0.07 per share.
| Operating Cash Flow | -934,832.00 |
| Capital Expenditures | -7.17M |
| Free Cash Flow | -8.11M |
| FCF Per Share | -0.07 |
Margins
RavenQuest BioMed Inc. operates with a gross margin of 58.63, reflecting its pricing power and cost economics. The operating margin of -1,199.47 and net profit margin of -2,125.41 provide insight into operational efficiency.
| Gross Margin | 58.63 |
| Operating Margin | -1,199.47 |
| Pretax Margin | -2,163.38 |
| Profit Margin | -2,125.41 |
| EBITDA Margin | -943.58 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -17.66 |
| FCF Yield | 13.56 |
Scores
RavenQuest BioMed Inc. posts an Altman Z-Score of -4.01, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -4.01 |